引用次数
引用: 68,201
H-指数: 104
I10-指数 : 360
出版物: 810
Parallelization of SPHC on the Intel iPSC/860
T.P. Hughes , A.J. Giancola
Bulletin of the American Physical Society 38 ( 5)
1993
S885 IN SEARCH OF THE RESIDUAL LEUKAEMIC CLONE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN TREATMENT-FREE REMISSION
I.S. Pagani , P. Dang , V.A. Saunders , R. Grose
HemaSphere 3 398
2019
S883 COMBINATION THERAPY USING ASCIMINIB PLUS IMATINIB (IMA) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY
A. Hochhaus , Y.T. Goh , P.D. Le Coutre , M. Sondhi
HemaSphere 3 397
2
2019
S884 COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY
M.J. Mauro , D.-W. Kim , J. Cortes , D. Réa
HemaSphere 3 397 -398
2
2019
Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
Marion M Roberts , P Dyson , C Rawling , D Thorp
Cytotherapy 5 ( 6) 534 -541
3
2003
Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH
DL White , CJ Hutchins , S Turczynowicz , J Suttle
Pathology 29 ( 3) 289 -293
8
1997
Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders.
D.M. Ross , T.P. Hughes
Pathology 40 ( 3) 231 -246
14
2008
PF411 ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)
F.-X. Mahon , C. Boquimpani , N. Takahashi , N. Benyamini
HemaSphere 3 158
1
2019
Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase
HUGHES TP
Blood 102
18
2003
Glucose Metabolism (GM) Changes in Nondiabetic Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib (NIL) or Imatinib (IM)
Jf Gautier , Delphine Rea , Giuseppe Saglio , Tp Hughes
DIABETES 62 A704 -A705
2013
PCR FOLLOWING ALLOGENEIC BMT FOR CML
DI MARKS , NCP CROSS , TP HUGHES , P OSHEA
EXPERIMENTAL HEMATOLOGY 20 ( 6) 706 -706
1992
USE OF PCR AFTER BMT FOR CML TO ASSESS PROGNOSIS
TP HUGHES , P OSHEA , G MORGAN , P MARTIAT
EXPERIMENTAL HEMATOLOGY 19 ( 6) 564 -564
1991
of a Collegiate Coaching Science Minor
Timothy Baghurst , Trish Hughes , Jason Bishop
High School Athletic Director Opinions of the Value and Desired Content of a Collegiate Coaching Science Minor.
Timothy Baghurst , Trish Hughes , Jason Bishop
Applied Research in Coaching & Athletics Annual 30 ( 2)
1
2015
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Petranel T. Ferrao , Leonie K. Ashman , Michelle J. Frost , Timothy P. Hughes
Molecular Cancer Therapeutics 1 ( 12) 1115 -1124
239
2002
Clinical value of PCR in diagnosis and follow-up of leukaemia and lymphoma: report of the third Workshop of the Molecular Biology/BMT study group.
Pier Franco Pignatti , Philippe Martiat , Gianpaolo Nadali , Dino Veneri
Leukemia 5 ( 6) 448 -451
18
1991
Long-term imatinib therapy promotes bone formation in CML patients. Commentary
Panagiota Kostakis , Andrew C. W. Zannettino , Barrie Vernon-Roberts , Stephen Fitter
Blood 111 ( 5)
2008
Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience
Susan Branford , Susan Branford , Devendra K Hiwase , David Yeung
Blood 130 1621 -1621
1
2017
Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
Javier Pinilla-Ibarz , Elisabetta Abruzzese , Carlo Gambacorti-Passerini , Philipp D. le Coutre
Blood 130 1617 -1617
1
2017
Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study
Robert Weinkove , Susan Branford , Susan Branford , Anthony P Schwarer
Blood 130 2898 -2898
2017